Northern Trust Corp Purchases 20,073 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Northern Trust Corp boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 10.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 219,986 shares of the biotechnology company's stock after buying an additional 20,073 shares during the quarter. Northern Trust Corp owned approximately 0.72% of AnaptysBio worth $2,913,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in AnaptysBio by 191.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock worth $1,130,000 after acquiring an additional 22,164 shares in the last quarter. SG Americas Securities LLC increased its position in shares of AnaptysBio by 35.0% in the fourth quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company's stock valued at $216,000 after buying an additional 4,231 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after buying an additional 644 shares in the last quarter. Jennison Associates LLC boosted its position in AnaptysBio by 1.6% during the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company's stock worth $3,563,000 after acquiring an additional 4,242 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in AnaptysBio by 3.8% during the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock worth $398,000 after purchasing an additional 1,111 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Guggenheim reaffirmed a "buy" rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday. Wedbush restated an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a report on Thursday. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.38.

AnaptysBio Stock Performance

AnaptysBio stock traded up $1.66 during midday trading on Thursday, reaching $22.56. 892,851 shares of the company's stock were exchanged, compared to its average volume of 610,714. AnaptysBio, Inc. has a 52 week low of $12.21 and a 52 week high of $41.31. The firm has a market cap of $662.81 million, a price-to-earnings ratio of -3.71 and a beta of -0.20. The stock's 50-day simple moving average is $19.65 and its 200 day simple moving average is $18.26.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $27.77 million during the quarter, compared to analysts' expectations of $15.27 million. Research analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has approved a stock buyback program on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its shares are undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.